<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04006964</url>
  </required_header>
  <id_info>
    <org_study_id>2/17</org_study_id>
    <nct_id>NCT04006964</nct_id>
  </id_info>
  <brief_title>Diagnostic Accuracy Of Forced Oscillation Technique To Detect Lung Function Anomalies</brief_title>
  <official_title>Diagnostic Accuracy Of Forced Oscillation Technique To Detect Lung Function Anomalies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Restech Srl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MGC Diagnostics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Restech Srl</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The diagnosis of a lung function anomaly requires the evaluation of pulmonary function by
      spirometry. However, some patients (e.g. children, elderly, or diseased individuals) may have
      difficulty performing the related forced maximal respiratory maneuver correctly. Forced
      Oscillation Technique (FOT) measures lung impedance during tidal breathing, requiring minimal
      patient cooperation. The purpose of this study is to establish the diagnostic accuracy of FOT
      parameters alone or in combination with lung volumes in detecting lung function anomalies as
      compared with spirometry and with the diagnosis made by the physician.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose and Rationale The diagnosis of a lung function anomaly requires the evaluation of
      pulmonary function by spirometry. However, some patients (e.g. children, elderly, or diseased
      individuals) may have difficulty performing the related forced maximal respiratory maneuver
      correctly. FOT measures lung impedance during tidal breathing, requiring minimal patient
      cooperation. The within-breath calculation of impedance allows separating the contribution of
      inspiration and expiration to the measured parameters. The purpose of this study is to
      establish the diagnostic accuracy of FOT parameters alone or in combination with lung volumes
      in detecting lung function anomalies as compared with spirometry and with the diagnosis made
      by the physician.

      Objectives Primary: To compare the diagnostic accuracy of FOT with spirometry to detect a
      lung function anomaly (i.e. an obstructive and/or restrictive respiratory disease).

      Secondary: To compare the diagnostic accuracy of FOT with the final diagnosis made by the
      physician (i.e. the diagnosis based on current guidelines) to detect a lung function anomaly
      (i.e. an obstructive and/or restrictive respiratory disease).

      Study Design This will be a multi-center prospective study of consecutive subjects attending
      the pulmonary function test laboratory for pulmonary function tests (PFT) or randomly taken
      from the clinical site's records among those with symptoms with two separate study phases, an
      Identification Phase and a Validation Phase. Subjects will undergo the same study procedures
      in both phases. After signing the Informed Consent, a medical history will be obtained, a
      physical examination performed, and PFT (FOT, spirometry and, if required by the physician to
      reach a final diagnosis, additional lung function measurements) will be performed.

      Identification Phase: Subject data will be used to identify two separate rules based on
      abnormal lung volumes and impedance (FOT) parameters that will maximize the accuracy in
      identifying a lung function anomaly. For the primary objective, the reference test for the
      determination of such lung anomaly will be spirometry. For the secondary objective, the
      reference test for the determination of the presence of a lung function anomaly will be the
      final diagnosis made by the physician.

      Validation Phase: A separate and independent dataset of subjects will be used to test the
      accuracy of the rules identified from analysis of the Identification Phase in detecting a
      lung function anomaly.

      Study Duration Subject participation will be completed in 1 day. Study duration is expected
      to be 7 months
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Decision rule that maximises sensitivity and specificity as compared with spirometry</measure>
    <time_frame>1 day</time_frame>
    <description>This will be a rule to detect lung anomalies as compared with spirometry that will be identified and validated in two separate populations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decision rule that maximises sensitivity and specificity as compared with physician's diagnosis</measure>
    <time_frame>1 day</time_frame>
    <description>This will be a rule to detect lung anomalies as compared with physician's final diagnosis that will be identified and validated in two separate populations</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">579</enrollment>
  <condition>Respiratory Disease</condition>
  <arm_group>
    <arm_group_label>Identification Group</arm_group_label>
    <description>Subjects &gt;= 3 years old will measure as a minimum FOT and spirometry. Final diagnosis will be made by the physician as per current guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Validation Group</arm_group_label>
    <description>Subjects &gt;= 3 years old will measure as a minimum FOT and spirometry. Final diagnosis will be made by the physician as per current guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Resmon PRO FULL v2</intervention_name>
    <description>Measurement of lung impedance by the Forced Oscillation Technique</description>
    <arm_group_label>Identification Group</arm_group_label>
    <arm_group_label>Validation Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The following age groups will be considered:

          -  Preschool children (3-5 years old)

          -  School-age children (6-11 years old)

          -  Adolescents (12-17 years old)

          -  Adults (&gt;= 18 years old)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects ≥3 years old attending the pulmonary function laboratory with an order
             for PFT or

          -  Subjects ≥3 years old randomly chosen from a database of subjects having respiratory
             symptoms at the time of inclusion into the database.

        Exclusion Criteria:

        - Subjects unable to provide written Informed Consent (or not provided by the participant's
        parent/guardian) and Assent Form (where applicable).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonello Fuso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University of the Sacred Heart</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefania La Grutta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto di Biomedicina e Immunologia Molecolare &quot;A. Monroy&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrico Lombardi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero, Universitaria Meyer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Kaminsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont Medical Center Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janos Porszasz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biomedical Research Institute at Harbor- UCLA Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felip Burgos Rincón, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic de Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessandro Gobbi</last_name>
    <phone>+390236593690</phone>
    <email>a.gobbi@restech.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pasquale Pompilio</last_name>
    <phone>+390236593690</phone>
    <email>p.pompilio@restech.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Biomedical Research Institute at Harbor- UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janos Porszasz, MD</last_name>
      <email>porszasz@ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center Inc.,</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Alan Kaminsky, MD</last_name>
      <email>david.kaminsky@med.uvm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero, Universitaria Meyer</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Lombardi, MD</last_name>
      <phone>39.055.566-2461</phone>
      <email>enrico.lombardi@meyer.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catholic University of the Sacred Heart</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonello Fuso, MD</last_name>
      <email>leonello.fuso@policlinicogemelli.it</email>
    </contact>
    <contact_backup>
      <last_name>Chiara Contu, MD</last_name>
      <phone>3487398380</phone>
      <email>chiara.contu@policlinicogemelli.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Istituto di Biomedicina e Immunologia Molecolare &quot;A. Monroy&quot;</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania La Grutta, MD</last_name>
      <phone>380 757 8052</phone>
      <email>lagrutta@ibim.cnr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felip Burgos Ricon, MD</last_name>
      <email>FBURGOS@clinic.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ginasthma.org</url>
    <description>Global Initiative for Asthma. Global strategy for asthma management and prevention, 2017.</description>
  </link>
  <reference>
    <citation>Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 2005 Nov;26(5):948-68.</citation>
    <PMID>16264058</PMID>
  </reference>
  <reference>
    <citation>Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. General considerations for lung function testing. Eur Respir J. 2005 Jul;26(1):153-61. Review.</citation>
    <PMID>15994402</PMID>
  </reference>
  <reference>
    <citation>Aurora P, Stocks J, Oliver C, Saunders C, Castle R, Chaziparasidis G, Bush A; London Cystic Fibrosis Collaboration. Quality control for spirometry in preschool children with and without lung disease. Am J Respir Crit Care Med. 2004 May 15;169(10):1152-9. Epub 2004 Mar 17.</citation>
    <PMID>15028561</PMID>
  </reference>
  <reference>
    <citation>Woodruff PG, Barr RG, Bleecker E, Christenson SA, Couper D, Curtis JL, Gouskova NA, Hansel NN, Hoffman EA, Kanner RE, Kleerup E, Lazarus SC, Martinez FJ, Paine R 3rd, Rennard S, Tashkin DP, Han MK; SPIROMICS Research Group. Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. N Engl J Med. 2016 May 12;374(19):1811-21. doi: 10.1056/NEJMoa1505971.</citation>
    <PMID>27168432</PMID>
  </reference>
  <reference>
    <citation>van Noord JA, Wellens W, Clarysse I, Cauberghs M, Van de Woestijne KP, Demedts M. Total respiratory resistance and reactance in patients with upper airway obstruction. Chest. 1987 Sep;92(3):475-80.</citation>
    <PMID>3622024</PMID>
  </reference>
  <reference>
    <citation>Zerah F, Lorino AM, Lorino H, Harf A, Macquin-Mavier I. Forced oscillation technique vs spirometry to assess bronchodilatation in patients with asthma and COPD. Chest. 1995 Jul;108(1):41-7.</citation>
    <PMID>7606989</PMID>
  </reference>
  <reference>
    <citation>Faria AC, Costa AA, Lopes AJ, Jansen JM, Melo PL. Forced oscillation technique in the detection of smoking-induced respiratory alterations: diagnostic accuracy and comparison with spirometry. Clinics (Sao Paulo). 2010;65(12):1295-304.</citation>
    <PMID>21340218</PMID>
  </reference>
  <reference>
    <citation>Dellacà RL, Santus P, Aliverti A, Stevenson N, Centanni S, Macklem PT, Pedotti A, Calverley PM. Detection of expiratory flow limitation in COPD using the forced oscillation technique. Eur Respir J. 2004 Feb;23(2):232-40.</citation>
    <PMID>14979497</PMID>
  </reference>
  <reference>
    <citation>Dellaca RL, Aliverti A, Lo Mauro A, Lutchen KR, Pedotti A, Suki B. Correlated variability in the breathing pattern and end-expiratory lung volumes in conscious humans. PLoS One. 2015 Mar 24;10(3):e0116317. doi: 10.1371/journal.pone.0116317. eCollection 2015.</citation>
    <PMID>25803710</PMID>
  </reference>
  <reference>
    <citation>Peslin R, Ying Y, Gallina C, Duvivier C. Within-breath variations of forced oscillation resistance in healthy subjects. Eur Respir J. 1992 Jan;5(1):86-92.</citation>
    <PMID>1577156</PMID>
  </reference>
  <reference>
    <citation>Dellacà RL, Pompilio PP, Walker PP, Duffy N, Pedotti A, Calverley PM. Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD. Eur Respir J. 2009 Jun;33(6):1329-37. doi: 10.1183/09031936.00139608. Epub 2009 Jan 22.</citation>
    <PMID>19164347</PMID>
  </reference>
  <reference>
    <citation>Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J; ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012 Dec;40(6):1324-43. doi: 10.1183/09031936.00080312. Epub 2012 Jun 27.</citation>
    <PMID>22743675</PMID>
  </reference>
  <reference>
    <citation>Beydon N, Davis SD, Lombardi E, Allen JL, Arets HG, Aurora P, Bisgaard H, Davis GM, Ducharme FM, Eigen H, Gappa M, Gaultier C, Gustafsson PM, Hall GL, Hantos Z, Healy MJ, Jones MH, Klug B, Lødrup Carlsen KC, McKenzie SA, Marchal F, Mayer OH, Merkus PJ, Morris MG, Oostveen E, Pillow JJ, Seddon PC, Silverman M, Sly PD, Stocks J, Tepper RS, Vilozni D, Wilson NM; American Thoracic Society/European Respiratory Society Working Group on Infant and Young Children Pulmonary Function Testing. An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children. Am J Respir Crit Care Med. 2007 Jun 15;175(12):1304-45. Review.</citation>
    <PMID>17545458</PMID>
  </reference>
  <reference>
    <citation>Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G. Standardisation of the measurement of lung volumes. Eur Respir J. 2005 Sep;26(3):511-22. Review.</citation>
    <PMID>16135736</PMID>
  </reference>
  <reference>
    <citation>Brazzale DJ, Hall GL, Pretto JJ. Effects of adopting the new global lung function initiative 2012 reference equations on the interpretation of spirometry. Respiration. 2013;86(3):183-9. doi: 10.1159/000352046. Epub 2013 Aug 14.</citation>
    <PMID>23949369</PMID>
  </reference>
  <reference>
    <citation>Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF; STARD Group. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. Clin Chem. 2015 Dec;61(12):1446-52. doi: 10.1373/clinchem.2015.246280. Epub 2015 Oct 28.</citation>
    <PMID>26510957</PMID>
  </reference>
  <reference>
    <citation>Fleiss, J. (1973) Statistical Methods for Rates and Proportions</citation>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 1, 2019</last_update_submitted>
  <last_update_submitted_qc>July 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

